1

THE ONLY oral immunostimulant recommended in the 2010 European 1 Association of Urology guidelines recommended for
immunoprophylaxis in female patients with recurrent uncomplicated UTI

Significant reduction in recurrences in patients 2 suffering from recurrent UTI

3.6
p<0.001

N=451

number of recurrences

0.9

Before treatment with Uro-Vaxom

After Uro-Vaxom treatment

-76%

1 capsule a day for 3 months

URO-VAXOM: ABRIDGED INFORMATION AS REQUESTED BY SWISSMEDIC C: lyophilized bacterial lysate: 6 mg. D: treatment of acute episodes: 1 caps./day on an empty stomach for at least 10 days; preventive/consolidation therapy: 1 caps./day on an empty stomach for 3 months. CI: hypersensitivity to the constituents of Uro-Vaxom. Pr: efficacy and safety not tested in children under 4 years. Pregnancy and breast-feeding: no clinical controlled studies available. AE: gastrointestinal disorders (diarrhea, nausea, abdominal pain, gastric discomfort, dyspepsia), skin reactions (allergic reactions, rash, pruritus, exanthema), nervous disorders (headache) and generalized problems (slight fever). Treatment should be stopped in case of skin reactions, oedema or fever (possible allergic reactions). For further information, please contact OM Pharma SA. 30 and 90 capsules. references 1 Grabe M, Bjerklund-Johansen T.E, Botto H, Cek M, Naber K.G, Tenke P, Wagenlehner F. Guidelines on urological infections. European Association of Urology 2010. 2 Tammen H., Frey Ch., Treatment of Recurrent Urinary Tract Infections with Uro-Vaxom. Open multicenter Study with 521 patients. Urologe (B) (1988) 28:294-296.

Uro-Vaxom

OM Pharma SA 22 rue du Bois-du-Lan P.O. Box 88 1217 Meyrin 2/Geneva Switzerland www.ompharma.com